Category News

Otsuka and Jolly Good Initiate Distribution of FACEDUO Content to Aid Families Supporting Individuals with Severe Social Withdrawal

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Jolly Good Inc. (Jolly Good) have commenced the delivery of innovative content aimed at supporting families of individuals in Japan grappling with severe social withdrawal (hikikomori) through the utilization of the social skills training…

Read MoreOtsuka and Jolly Good Initiate Distribution of FACEDUO Content to Aid Families Supporting Individuals with Severe Social Withdrawal

Sanofi’s Scientific Leadership in Inflammatory Diseases Showcased with New Data at AAAAI Presentation

Sanofi’s Leading Role in Addressing Inflammatory Diseases Highlighted at AAAAI Conference The latest data presented at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting sheds light on Sanofi’s robust scientific leadership in managing inflammatory diseases. Among the…

Read MoreSanofi’s Scientific Leadership in Inflammatory Diseases Showcased with New Data at AAAAI Presentation

Labcorp Introduces Innovative Test for Assessing Risk and Predicting Severity of Preeclampsia in Expectant Mothers

Labcorp (NYSE: LH), a renowned provider of cutting-edge and all-encompassing laboratory services globally, has introduced and made accessible a recently FDA-cleared blood test. This test is designed for evaluating the risk and overseeing the clinical aspects of severe preeclampsia, a…

Read MoreLabcorp Introduces Innovative Test for Assessing Risk and Predicting Severity of Preeclampsia in Expectant Mothers

Staying Alert and Taking Precautions During Lunar New Year Celebrations Amidst Avian Influenza Concerns

Enhanced Precautions and Vigilance for Avian Influenza during Lunar New Year Celebrations in Asia As preparations for Lunar New Year festivities in Asia gain momentum, the increased trading and handling of poultry, coupled with the imminent travel rush, have prompted…

Read MoreStaying Alert and Taking Precautions During Lunar New Year Celebrations Amidst Avian Influenza Concerns

Priority Review Granted in the US for Enhertu in Patients with Metastatic HER2-Positive Solid Tumors

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry…

Read MorePriority Review Granted in the US for Enhertu in Patients with Metastatic HER2-Positive Solid Tumors

EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRAHIGH-DOSE FORMULATION IN JAPAN FOR THE INDICATION OF AMYOTROPHIC LATERAL SCLEROSIS

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices…

Read MoreEISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRAHIGH-DOSE FORMULATION IN JAPAN FOR THE INDICATION OF AMYOTROPHIC LATERAL SCLEROSIS